California startup Cognixion just announced it's launching clinical trials to integrate its non-invasive brain-computer interface with the Apple Vision Pro, giving paralyzed patients with speech disorders a way to communicate through thought alone. The breakthrough could democratize BCI technology without requiring risky brain surgery, potentially reaching patients years ahead of invasive competitors like Neuralink.
The brain-computer interface race just took an unexpected turn. While Neuralink grabs headlines with surgical implants, Santa Barbara-based Cognixion is betting on a completely different approach - one that doesn't require cutting into anyone's skull.
The company announced today it's launching a clinical trial that pairs its wearable BCI technology with Apple's Vision Pro, targeting up to 10 participants with speech impairments from conditions like ALS, stroke, and spinal cord injuries. The timing couldn't be more strategic, coming just months after Apple opened its doors to assistive technology developers.
"In order to democratize access, you need to do it in such a way that's the least risky and the most acceptable for adoption for the majority of people," CEO Andreas Forsland told Wired. His personal motivation runs deep - the company emerged from his experience watching his intubated mother struggle to communicate in the ICU.
Cognixion's system works by swapping out Apple's standard headband for one embedded with six EEG sensors that monitor the brain's visual and parietal cortex. When users focus their mental attention on interface options, the system detects these "visual fixation signals" and translates them into commands. A separate neural computing pack processes the brain data outside the Vision Pro headset.
The company already proved the concept works. In earlier trials with its purpose-built Axon-R headset, ALS patients achieved communication speeds approaching normal conversation. One participant - a rabbi with ALS - demonstrated the technology by thoughtfully responding to questions about staying positive despite his diagnosis.
But the Vision Pro integration represents something bigger than just another medical device. "The Vision Pro gives you all of your apps, the app store, everything you want to do," Forsland explained. Instead of being limited to basic communication, users get access to Apple's entire ecosystem.
Apple laid the groundwork for this collaboration in May when it announced new accessibility protocols allowing users with severe mobility disabilities to control iPhones, iPads, and Vision Pro devices without physical movement. The move opened doors for multiple BCI companies - Synchron, which uses blood vessel implants, has also integrated with the Vision Pro platform.
The technical challenge remains formidable. UCLA BCI researcher Jonathan Kao, who isn't involved with Cognixion, points out the fundamental limitation: "No one has been able to put out a consumer device that matches the performance of an invasive device or even comes close. The signal quality is very poor so it's a challenge to decode quickly, reliably, and robustly."
That's where Cognixion's AI advantage comes in. Chief Technology Officer Chris Ullrich explained their approach: "We actually build an AI for each individual participant that is customized with their history of speaking, their style of their humor, anything they've written, anything they've said, that we can gather. We crunch all that down into something that is a user proxy."
This personalized AI acts as a communication copilot, offering contextually relevant suggestions while users compose their thoughts. The system can fall back on eye tracking or head movement when brain signal quality drops, but the EEG capability becomes crucial for patients with severe motor disabilities.
The regulatory path looks promising compared to surgical alternatives. While invasive BCIs face years of safety trials, Cognixion's non-invasive approach sidesteps the biggest risks. The FDA will likely evaluate the device based on user-friendliness and quality of life improvements rather than surgical safety concerns.
Cognixion plans a larger pivotal trial with around 30 patients following this initial study. The timeline could put them in patients' hands years before surgical competitors complete their safety assessments.
The broader implications extend beyond any single company. If AI copilots can successfully bridge the performance gap between invasive and non-invasive BCIs, it could reshape the entire industry's approach to brain-computer interfaces. As Kao noted, "we could have a widespread device that doesn't require surgery."
Cognixion's integration with the Vision Pro represents a pivotal moment in assistive technology - the convergence of consumer tech giants with specialized medical innovation. While invasive BCIs chase theoretical performance peaks, non-invasive approaches like Cognixion's could reach patients who need help communicating right now. The real test isn't just technical capability, but whether AI can make brain-computer interfaces accessible enough for widespread adoption. If this trial succeeds, it might prove that sometimes the best path forward doesn't require the most extreme measures.
